Xenon Pharmaceuticals Culture d’entreprise

Mr. Robin P. Sherrington, PhD has been Senior Vice President of Business & Corporate Development at Xenon Pharmaceuticals Inc. since February 2012. Mr. Sherrington served as Vice President of Business & Corporate Development at Xenon Pharmaceuticals Inc. and also served as its Senior Director, Strategic Alliances. He joined Xenon in 2001 and has 17 years of biopharmaceutical industry experience. He played the lead role in establishing Xenon's pharma collaborations with Roche, Takeda, Merck, Isis and Genentech, Xenon's collaborations with GenomeBC, IRAP and CDRD and also has responsibilities for the alliance management of these partnerships. He spent time leading the pain program identifying XEN402 and steering the product into its clinical studies. He was the Head of Xenon's human genetic discovery and validation group where under his stewardship, multiple novel drug targets were validated in humans including the targets constituting Xenon's current pipeline. Mr. Sherrington was a neuroscientist at Pfizer and Parke-Davis, as well as the biotechnology companies Axys Pharmaceuticals and Sequana Therapeutics. He has over 56 peer reviewed publications, including five Nature papers and is an inventor on multiple patents. Mr. Sherrington is a regular guest speaker at Canadian and international business and scientific meetings. Mr. Sherrington received his PhD from the University College London in the UK and post-doctoral training at University of Toronto, where he cloned the presenilin Alzheimer's disease genes.

Dr. James R. Empfield, PhD has been Senior Vice President of Drug Discovery of Xenon Pharmaceuticals USA Inc atXenon Pharmaceuticals Inc. since February 9, 2016. Prior to joining Xenon, Dr. Empfield served as Vice President, Drug Discovery and Chemistry; Co-Head of Research, Boston at Vertex Pharmaceuticals Inc. from 2011 to August 2015. At Vertex, Dr. Empfield was jointly responsible for the oversight of the operations and portfolio of the Boston research organization including the delivery of drug candidates from lead optimization projects into preclinical development. From 2006 to 2011, Dr. Empfield was Director, CNS Chemistry Department at AstraZeneca Pharmaceuticals LP and held various other positions at AstraZeneca from 1990 to 2006. Dr. Empfield has a Ph.D. in Chemistry from the University of Pennsylvania, an M.S. in Chemistry from Bucknell University and a B.S. in Chemistry from Lebanon Valley College.

Mr. Ian C. Mortimer, MBA, CPA, CMA, has been the Chief Financial Officer of Xenon Pharmaceuticals Inc. since October 2013 and has been its Chief Operating Officer since March 12, 2015 and has been its Corporate Secretary since June 2015. Mr. Mortimer has over 20 years experience in the biotechnology sector. He served as the Chief Financial Officer of Tekmira Pharmaceuticals Corp. from December 17, 2004 to October 7, 2013 and its Executive Vice President of Finance from May 2008 to October 7, 2013. He was responsible for all aspects of Tekmira's finance and capital markets activities. He is accredited with leading both Xenon's and Tekmira's listings on the NASDAQ, in 2014 and 2010 respectively. He served as Director of Investor Relations at Marret Resource Corp. He joined Marret Resource Corp.(alternate name Primary Corp.) in 1997. He served as Chief Financial Officer and Executive Vice President of Finance at Protiva Biotherapeutics, Inc. He served as an Executive Vice President at Tekmira Pharmaceuticals Corp. and Senior Vice President of Finance since December 17, 2004. Prior to his most recent position at Tekmira, he served as Chief Financial Officer at Inex Pharmaceuticals Corporation. He served as the Chief Financial Officer and Vice President of Finance of Primary Corp. since December 17, 2004. He served as Director of Investor Relations at Primary Corp. In 2004, he was recognized as Best Investor Relations Officer for a Small Cap Company in Canada. He has been Director of Appili Therapeutics Inc. since November 2017. He served as Director of Primary Corp. and Marret Resource Corp. since April 30, 2007. He is a Chartered Professional Accountant and Certified Management Accountant. He has a B.Sc. in Microbiology from the University of British Columbia and an M.B.A. from Queen's University and is a Certified Management Accountant.

Dr. Y. Paul Goldberg, MB, ChB, PhD, FRCPC, has been Senior Vice President of Clinical Development at Xenon Pharmaceuticals Inc. since March 2017 and served as its Vice President of Clinical Development since February 2010. Dr. Goldberg joined Xenon in 2000. He is internationally recognized in the field of iron metabolism, particularly for the discovery of the hemojuvelin protein underlying Juvenile Hemochromatosis. His discovery of the NaV1.7 sodium channel gene underlying Congenital Indifference to Pain has provided key insight into the development of novel analgesics and this data is now utilized throughout the pharmaceutical industry. Dr. Goldberg has been a regular guest speaker at local and international scientific meetings. He has coauthored 53 peer review journal publications, 2 book chapters and is an inventor on 6 patents. Dr. Goldberg's research concentrated on the molecular aspects of human genetic diseases, particularly Huntington disease where he made seminal contributions to the delineation of the molecular genetics and coauthored over 35 peer-reviewed articles on this disease. Prior to his specialization in clinical genetics at the University of British Columbia (2000), he obtained his PhD through the University of Cape Town in 1990 in the field of cancer genetics.